RedHill Biopharma (RDHL) Total Debt (2020 - 2022)

RedHill Biopharma (RDHL) has 3 years of Total Debt data on file, last reported at $115.2 million in Q4 2022.

• Total Debt for Q4 2022 came in at $115.2 million, down 31.11% year-over-year; the trailing twelve-month figure through Dec 2022 was $115.2 million (down 31.11% YoY), and the FY2022 annual result was $115.2 million, down 31.11% from the prior year.
• Total Debt improved to $115.2 million in Q4 2022 per RDHL's latest filing, from $113.9 million in the prior quarter.
• Over five years, Total Debt peaked at $167.2 million in Q4 2021 and troughed at $78.2 million in Q1 2020.
• A 3-year average of $101.5 million and a median of $84.5 million in 2021 frame the typical range for Total Debt.
• On a YoY basis, Total Debt climbed as much as 36.33% in 2022 and fell as far as 31.11% in 2022.
• A 3-year view of Total Debt shows it stood at $162.8 million in 2020, then advanced by 2.74% to $167.2 million in 2021, then sank by 31.11% to $115.2 million in 2022.
• Business Quant data shows RDHL's Total Debt at $115.2 million in Q4 2022, $113.9 million in Q3 2022, and $85.5 million in Q2 2022.